UnknownNot Applicable

Oligo-Fucoidan Decrease Lung Radiation Damage

Taiwan100 participantsStarted 2022-03-30

Plain-language summary

Fucoidan is FDA approved and in common use for treatment of angina. These studies will advance that work to human use. Successful mitigation of lung radiation damage and heart toxicity will improve the quality of life in veterans and non-veterans who are treated for lung cancer by radiation, and may also improve cure rates of radiation therapy for lung cancer.

Who can participate

Age range20 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Ages Eligible for Study: 20-90 years old
✓. Men and women undergoing radiation therapy for lung cancer，no matter the radiation therapy is for curing or for palliating.
✓. Karnofsky performance status，KPS \> 70
✓. Absolute Neutrophils \> 1000/mm\^3
✓. Platelets \> 75,000/mm\^3
✓. Hematocrit \> 25%.
✓. Liver and kidney function tests will be within normal range
✓. Baseline blood pressure will be systolic \> 110 mmHg sitting

Exclusion criteria

✕. Patients who get lung cancer but no need or without the willingness of radiation therapy
✕. Patients who are taking antiHTN drugs
✕. Women of pregnant, lactating, childbearing potential, or with the intention of becoming pregnant
✕. Patients who are presently participating in another clinical study (except for follow-up surveys for study outcomes)
✕. Patients who are judged to be ineligible for study entry by the investigator or subinvestigator

What they're measuring

Number of Participants With Radiation Pneumonitis

Timeframe: 6 months

Trial details

NCT IDNCT05616507

SponsorTaipei Medical University WanFang Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-30

Contact for this trial

Szu-Yuan Wu

+886910603955 szuyuanwu5399@gmail.com

View on ClinicalTrials.gov More Radiation Toxicity trials